Stoke Therapeutics, Inc. (NASDAQ:STOK) Director Edward M. Md Kaye Sells 10,382 Shares

Stoke Therapeutics, Inc. (NASDAQ:STOK) Director Edward M. Md Kaye sold 10,382 shares of the business’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $90,011.94. Following the sale, the director now owns 148,253 shares of the company’s stock, valued at approximately $1,285,353.51. This represents a 6.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Stoke Therapeutics Stock Up 0.8 %

NASDAQ STOK traded up $0.07 during trading hours on Thursday, reaching $8.33. The company’s stock had a trading volume of 1,070,583 shares, compared to its average volume of 833,189. The firm’s 50-day moving average price is $9.50 and its 200-day moving average price is $11.51. Stoke Therapeutics, Inc. has a 1 year low of $5.60 and a 1 year high of $17.58. The company has a market capitalization of $441.22 million, a price-to-earnings ratio of -3.97 and a beta of 0.99.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.38. The company had revenue of $22.61 million for the quarter, compared to analysts’ expectations of $4.20 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. Equities research analysts anticipate that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

Institutional Trading of Stoke Therapeutics

Several hedge funds have recently modified their holdings of STOK. Intech Investment Management LLC purchased a new stake in shares of Stoke Therapeutics during the 3rd quarter worth approximately $160,000. Charles Schwab Investment Management Inc. raised its holdings in Stoke Therapeutics by 9.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 316,134 shares of the company’s stock valued at $3,885,000 after buying an additional 26,870 shares during the period. BNP Paribas Financial Markets raised its holdings in Stoke Therapeutics by 1,589.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company’s stock valued at $936,000 after buying an additional 71,647 shares during the period. Checkpoint Capital L.P. purchased a new stake in Stoke Therapeutics during the 3rd quarter valued at $1,936,000. Finally, RTW Investments LP raised its holdings in Stoke Therapeutics by 10.1% during the 3rd quarter. RTW Investments LP now owns 4,652,285 shares of the company’s stock valued at $57,177,000 after buying an additional 427,447 shares during the period.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Chardan Capital reaffirmed a “buy” rating and set a $24.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research report on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $47.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $23.00.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.